--------------------------------
OMB APPROVAL
--------------------------------
OMB Number: 3235-0167
Expires: October 31, 2004
Estimated average burden hours
per response.......1.50
--------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-19290
------------------
COR THERAPEUTICS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
256 E. GRAND AVENUE, SOUTH SAN FRANCISCO, CALIFORNIA 94080
- --------------------------------------------------------------------------------
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
5% CONVERTIBLE SUBORDINATED NOTES DUE MARCH 1, 2007
4.50% CONVERTIBLE SENIOR NOTES DUE JUNE 15, 2006
- --------------------------------------------------------------------------------
(Title of each class of securities covered by this Form)
COMMON STOCK, $.0001 PAR VALUE PER SHARE
- --------------------------------------------------------------------------------
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) / / Rule 12h-3(b)(1)(i) /X/
Rule 12g-4(a)(1)(ii) / / Rule 12h-3(b)(1)(ii) / /
Rule 12g-4(a)(2)(i) / / Rule 12h-3(b)(2)(i) / /
Rule 12g-4(a)(2)(ii) / / Rule 12h-3(b)(2)(ii) / /
Rule 15d-6 / /
Approximate number of holders of record as of the certification or notice
date: 61 holders of 5% Convertible Subordinated Notes due March 1, 2007 and 75
holders of 4.50% Convertible Senior Notes due June 15, 2006.
Pursuant to the requirements of the Securities Exchange Act of 1934 COR
Therapeutics, Inc. has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.
Date: FEBRUARY 12, 2002 By: /S/ JOHN B. DOUGLAS III
------------------------ --------------------------------
John B. Douglas III
President
Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the
General Rules and Regulations under the Securities Exchange Act of 1934. The
registrant shall file with the Commission three copies of Form 15, one of which
shall be manually signed. It may be signed by an officer of the registrant, by
counsel or by any other duly authorized person. The name and title of the person
signing the form shall be typed or printed under the signature.
POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF
SEC 2069 (3-99) INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO
RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB
CONTROL NUMBER.